events.bizzabo.com Open in urlscan Pro
52.1.163.193  Public Scan

Form analysis
0 forms found in the DOM

Text Content

This is what your event will look like after going live
 * No notifications yet.

 * Sign Out

Toggle navigation

 * 
 * Home
 * Agenda
 * Speakers
 * Sponsors

 *  * No notifications yet.
   
    * Sign Out


view session


1 Sessions
Time


Log in

All Days

Tue Feb 07

Wed Feb 08

Thu Feb 09

Fri Feb 10

Sat Feb 11


All Sessions (1)
(1)

My Interests


Tue Feb 07
8:00 AM
8:00 AM - 9:00 AM PST / 4:00 PM - 5:00 PM Your local time   (1 hour)
Spectral Flow Cytometry in the Clinical Arena

Broadcast

Starts 2 min before the session time

A robust platform for immune monitoring and biomarker discovery in clinical
trials

As the importance of cellular biomarkers in the drug development process grows,
the value of deep immune profiling, achieved through high-parameter single-cell
analysis, has the potential to dramatically increase our understanding of the
immune landscape in the context of disease and treatment. When adopted into a
clinical setting, the expanded knowledge from large parameter datasets, often
generated from limited sample volumes, could alter our approach to drug
discovery and efficacy.  Spectral Flow Cytometry (SFC) has shifted the
long-standing paradigm of one fluorochrome / one detector measurement by
capturing the full emission spectrum across each laser used in the system.  This
advancement, coupled with the ongoing development of spectrally unique dyes,
makes SFC particularly well suited to support the growing requirement for
superior resolution, increased sensitivity, and more comprehensive
immunophenotyping in the clinical arena.  Given both the complexity of
high-parameter flow cytometry assays and the global nature of clinical trials,
minimization of variability through instrument and assay harmonization and
standardization is essential for data reproducibility.  Successful platform
adoption relies on defining and limiting variability to support the intended
context of use.  As such, condition-specific instrument performance
qualification through the generation of Cross Stain Index (CSI) (and/or
Spillover Spread Matrix (SSM)) represents a powerful tool to confirm intra- and
inter-instrument harmonization across a global fleet.  Following standardization
to a single set of target MFI values, high-parameter assays optimized and
validated as fit-for-purpose can be transferred to multiple instruments, across
a global flow cytometry delivery network. The successful implementation of these
steps results in the generation of consistent population frequency and
fluorescent intensity outputs from high-parameter assays. The Cytek® Aurora
spectral flow cytometer has demonstrated the ability to be a robust platform for
immune monitoring and biomarker discovery in clinical trials.

Key topics discussed in the webinar will include:

 * Application of spectral flow cytometry in clinical trials; opportunities,
   risks, and recommendations
 * Pathway to successful platform adoption including instrument harmonization,
   instrument standardization, and assay validation
 * Assay performance at standardized settings

Who should attend?

 * Flow cytometry users looking to minimize variation and ensure data
   reproducibility, especially across multiple instruments and/or multiple sites
 * Scientists using flow cytometry for immune monitoring and biomarker discovery
   in clinical trials
 * Anyone interested in flow cytometry fundamentals

Megan McCausland
Scientific Advisor, Flow Cytometry
Q2 Solutions
Speaker
Dr. Emily Frieben
Editor
Current Protocols
Moderator

Add to calendar: Google iCal Outlook Yahoo

Looking for your ticket? Contact the organizer
Add to calendar: Google iCal Outlook Yahoo
Looking for your ticket? Contact the organizer

PLEASE ENABLE COOKIES

We use cookies to show your personalized agenda, broadcast virtual sessions, and
offer engagement tools. Without enabling them, you will not be able to complete
the login.
Click here to learn how to enable cookies for this website
Cancel
Done